Supernus Pharmaceuticals Inc. (SUPN) Downgraded by Zacks Investment Research
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
Several other equities analysts have also issued reports on the company. Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price for the company. in a report on Monday, July 18th. Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a report on Monday, July 18th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $28.00 target price (up from $23.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $25.25.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/supernus-pharmaceuticals-inc-supn-downgraded-by-zacks-investment-research.html
Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 20.85 on Tuesday. The stock’s 50 day moving average price is $23.53 and its 200-day moving average price is $20.40. Supernus Pharmaceuticals has a 12-month low of $9.51 and a 12-month high of $26.84. The firm has a market cap of $1.03 billion, a PE ratio of 42.55 and a beta of 1.73.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.05. The company earned $50.40 million during the quarter, compared to analyst estimates of $49.67 million. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. Supernus Pharmaceuticals’s quarterly revenue was up 43.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.03 earnings per share. Equities research analysts anticipate that Supernus Pharmaceuticals will post $0.68 earnings per share for the current fiscal year.
In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the stock in a transaction on Friday, September 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the completion of the transaction, the chief financial officer now directly owns 3,616 shares of the company’s stock, valued at $90,400. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 6.10% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. TIAA CREF Investment Management LLC raised its position in Supernus Pharmaceuticals by 37.0% in the first quarter. TIAA CREF Investment Management LLC now owns 190,959 shares of the specialty pharmaceutical company’s stock worth $2,912,000 after buying an additional 51,580 shares during the last quarter. Teachers Advisors Inc. raised its position in Supernus Pharmaceuticals by 9.1% in the first quarter. Teachers Advisors Inc. now owns 550,195 shares of the specialty pharmaceutical company’s stock worth $8,390,000 after buying an additional 46,100 shares during the last quarter. BlackRock Fund Advisors raised its position in Supernus Pharmaceuticals by 1.1% in the first quarter. BlackRock Fund Advisors now owns 2,826,989 shares of the specialty pharmaceutical company’s stock worth $43,112,000 after buying an additional 31,238 shares during the last quarter. Nicholas Investment Partners LP bought a new position in Supernus Pharmaceuticals during the first quarter worth approximately $1,990,000. Finally, Granahan Investment Management Inc. MA bought a new position in Supernus Pharmaceuticals during the first quarter worth approximately $5,945,000. 94.62% of the stock is owned by institutional investors and hedge funds.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.